drug
perfluorohexyloctane
Marketedupdated 5mo agoby $BLCO Bausch & Lomb Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1all catalysts(0)
nothing on the calendar yet
Trials studying perfluorohexyloctane
- phase4BL-RX01-TFSTAB-1402
- phase4SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease
- phase2A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
- phase4A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy
- phase4A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
- phase3A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
- phase4A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease
- phase4A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 18, 2028
~1.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Jun 21, 2037method-of-use (U-1900)US 10507132
- Sep 29, 2036formulationUS 11357738
- Oct 1, 2035method-of-use (U-1900)US 10576154
- Sep 12, 2033method-of-use (U-1900)US 10058615
- Sep 12, 2033method-of-use (U-1900)US 10369117
- Sep 12, 2033method-of-use (U-1900)US 10449164
FDA exclusivities (1)
- May 18, 2028NCENew Chemical Entity (5y)1.6y
News(2)
- Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trialA real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.biopharma_dive · 1mo ago
- Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage failWhile Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset showed significant superiority at day 15.biospace · 1mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that